CSS
SGTX

Cubist Systematic Strategies’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Cubist Systematic Strategies’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,463
Closed -$107K – 3712
2021
Q3 		$107K Sell
1,463
-29
-2% -$2.23K ﹤0.01% 2731
2021
Q2 		$208K Buy
+1,492
New +$262K ﹤0.01% 2536

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cubist Systematic Strategies's SGTX Position: Q4 2021 in Review

Cubist Systematic Strategies sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q4 2021, closing a stake of 1,463 shares — an estimated $107K sold.

Cubist Systematic Strategies first reported a position in SGTX in Q2 2021 and held it in 2 quarters. The position peaked at $208K in Q2 2021. 50 funds tracked by Wall St. Rank hold SGTX as of Q4 2021.

  • Cubist Systematic Strategies reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Cubist Systematic Strategies sold 1,463 Sigilon Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $107K.
  • Cubist Systematic Strategies first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Cubist Systematic Strategies's Sigilon Therapeutics, Inc. Common Stock position peaked at $208K in Q2 2021.
  • 50 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Cubist Systematic Strategies's 13F filing for Q4 2021, filed 14 Feb 2022.